References
- Global Cancer Facts & Figures. American Cancer Society (2018). www.cancer.org/research/cancer-facts-statistics/global.html.
- Herper M. Forbes, Pharma & Healthcare (2015). www.forbes.com/sites/matthewherper/2015/05/05/cancer-drugsales-approach-100-billion-and-could-increase-50-by-2018/-5410160270f4.
- Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5(3), 161–171 (2005).
- Mukherjee S, Das S, Nuthi S, Patra CR. Biocompatible nickel-prussian blue@ silver nanocomposites show potent antibacterial activities. Future Sci. OA 3(4), FSO233 (2017).
- Mukherjee S, Patra CR. Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics. Future Sci. OA 3(3), FSO203 (2017).
- Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438(7070), 932–936 (2005).
- Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 407(6801), 242–248 (2000).
- Caporarello N, Lupo G, Olivieri M et al. Classical VEGF, notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions. Mol. Med. Rep. 16(4), 4393–4402 (2017).
- Mukherjee S, Patra CR. Therapeutic application of antiangiogenic nanomaterials in cancers. Nanoscale 8(25), 12444–12470 (2016).
- Hashemi GN, Ghiyami-Hour F, Jahangiri S et al. Nanoparticles as new tools for inhibition of cancer angiogenesis. J. Cell Physiol. 233(4), 2902–2910 (2018).
- Abdalla AM, Xiao L, Ullah MW, Yu M, Ouyang C, Yang G. Current challenges of cancer antiangiogenic therapy and the promise of nanotherapeutics. Theranostics 8(2), 533–548 (2018).
- Mukherjee S, Nethi SK, Patra CR. Green synthesized gold nanoparticles for future biomedical applications. In: Particulate Technology for Delivery of Therapeutics. Springer, Singapore, 359–393 (2017).
- Mukherjee P, Bhattacharya R, Wang P et al. Antiangiogenic properties of gold nanoparticles. Clin. Cancer Res. 11(9), 3530–3534 (2005).
- Pan P, Ding H, Qin L et al. Gold nanoparticles induce nanostructural reorganization of VEGFR2 to repress angiogenesis. J. Biomed. Nanotechnol. 9(10), 1746–1756 (2013).
- Setyawati MI, Leong DT. Mesoporous silica nanoparticles as an antitumoral-angiogenesis strategy. ACS Appl. Mater. Interfaces 9(8), 6690–6703 (2017).
- Song H, Wang W, Zhao P et al. Cuprous oxide nanoparticles inhibit angiogenesis via downregulation of VEGFR2 expression. Nanoscale 6(6), 3206–3216 (2014).
- Grodzik M, Sawosz E, Wierzbicki M et al. Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo. Int. J. Nanomed. 6, 3041–3048 (2011).
- Mukherjee S, Sriram P, Barui AK et al. Graphene oxides show angiogenic properties. Adv. Healthc. Mater. 4(11), 1722–1732 (2015).
- Giri S, Karakoti A, Graham RP et al. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS ONE 8(1), e54578 (2013).
- Gurunathan S, Lee KJ, Kalishwaralal K et al. Antiangiogenic properties of silver nanoparticles. Biomaterials 30(31), 6341–6350 (2009).
- Gu G, Hu Q, Feng X et al. Biomaterials 35(28), 8215–8226 (2014).